xumengxia 2018-11-29 10:44 IP:未知
文獻(xiàn)標(biāo)題及相關(guān)信息如下: 1.Safety data for chemical products-Content and order of sections[s] . ISO 11014-2009, 2009 2.ZHANG Li, LU Ying. Problems incountering for danger chemicals registing work in Jiangsu[J] . Chemical Safety & Environment,2007, 1( 12) : 8-12 3.EU, Regulation( EC) No 1272 /2008 of European Parliament and of the Council of 16 December 2008 on classification, labelling and packing of substances and amending Regulation( EC) No1907 /2006[z], 2008 4.Hazard Communication. 29 CFR 1910. 1200 5.SHA Xi-dong,JIANG Hong, LI Li-xia. Study on classification of major hazard installation of hazardous chemicals[J] . Journal of Safety Science and Technology, 2011,7 ( 3) : 37-41 備注:提供PDF電子檔原件   [更多]
懸賞
¥50.00
已托管
載入中...
kebog 2018-12-06 11:16 IP:上海
求購磷酸西格列汀片信息   [更多]
懸賞
¥50.00
已托管
載入中...
wheataphid 2018-12-04 11:42 IP:北京
求購“Formulated Preparations: Specific Monographs: Amlodipine Besilate Tablets”《 BP2019 》的藥典標(biāo)準(zhǔn)一份.   [更多]
懸賞
¥50.00
已托管
載入中...
tan1990 2018-11-15 16:28 IP:重慶
高價(jià)求《云南省中藥飲片標(biāo)準(zhǔn)》葛根粉云信息,如果你有標(biāo)準(zhǔn),請聯(lián)系我,價(jià)格可談   [更多]
懸賞:
懸賞
¥200.00
已托管
載入中...
yyyyy0738 2018-11-28 08:27 IP:長沙
求購聚乙二醇4000 EP9.1標(biāo)準(zhǔn)一份   [更多]
懸賞
¥50.00
已托管
載入中...
butterfly 2018-11-09 14:00 IP:北京
標(biāo)題:求購 注射用亞胺培南西司他丁鈉2015年至2018年銷售數(shù)據(jù) 詳細(xì)要求: 需求名稱:求購 注射用亞胺培南西司他丁鈉2015年至2018年銷售數(shù)據(jù) 具體要求:要求數(shù)據(jù)清晰明了,注明出處、來源 要求時(shí)間:請?jiān)?018年11月15日之前 交稿方式:直接點(diǎn)擊交稿在線交稿就是了,我會(huì)每天過來看的,謝謝各位藥智的戰(zhàn)友們   [更多]
懸賞
¥90.00
已托管
載入中...
momo940325 2018-05-11 10:28 IP:重慶
1.廣東省中藥炮制規(guī)范1984年版 2.山東省中藥炮制規(guī)范 2002年版 3.江蘇省中藥飲片炮制規(guī)范2002版 4. 青海省藏藥炮制規(guī)范2010版 5.新建維吾爾自治區(qū)中藥加工炮制規(guī)范(2010版) 6.甘肅省中藥炮制規(guī)范(2009年版) 7.湖北省中藥飲片炮制規(guī)范 2009年版 8.北京市中藥飲片切制經(jīng)驗(yàn)1960版 9.北京市中藥飲片切制規(guī)范 (上+下兩冊)1975版 10.北京市中藥炮制規(guī)范 1986年版 11.中藥切制規(guī)范(武漢中醫(yī)藥協(xié)會(huì)) 12.中藥飲片切制規(guī)范(天津衛(wèi)生局1975版) 13.云南省中藥咀片炮灸規(guī)范1974版 14.青海省中藥炮制規(guī)范(1991年版) 15.廣東省中藥材飲片加工炮制手冊1977版 16.中草藥炮制規(guī)范(武漢革委會(huì)1979版) 17.河北中藥材炮制規(guī)范 1979版 18.山西中藥炮制規(guī)范1984 19.《河北省中藥材標(biāo)準(zhǔn)》(試行)2017版 20.中藥飲片炮制規(guī)范(沈陽市衛(wèi)生局) 1962 21.上海市中藥飲片炮制規(guī)范1962、1973、1980 22.四川省中藥飲片炮制規(guī)范2002版   [更多]
懸賞:
懸賞
¥1000.00
已托管
載入中...
xumengxia 2018-11-07 09:53 IP:未知
1、Analytical method transfer using equivalence tests with reasonable acceptance criteria and appropriate effort: extension of the ISPE concept 2、Using total error as decision criterion in analytical method transfer 3、Application of the equivalence test according to a concept for analytical method transfers from the International Society for Pharmaceutical Engineering (ISPE) 4、Application of the equivalence test for analytical method transfers: Testing precision using the United States Pharmacopoeia concept< 1 0 1 0 5、Blade-Font, Artur; Rocabayera, Teodoro de Mas - [Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1982, p. 841 - 848]   [更多]
懸賞
¥50.00
已托管
載入中...
xumengxia 2018-10-31 09:46 IP:未知
文獻(xiàn)標(biāo)題: 1:"kidney Int. 2015 Jul;88(1):17-27. doi: 10.1038/ki.2015.59. Epub 2015 Mar 18. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Chapman AB1, Devuyst O2, Eckardt KU3, Gansevoort RT4, Harris T5, Horie S6, Kasiske BL7, Odland D8, Pei Y9, Perrone RD10, Pirson Y11, Schrier RW12, Torra R13, Torres VE14, Watnick T15, Wheeler DC16; Conference Participants." 2:"Kidney Int. 2015 Oct;88(4):676-83. doi: 10.1038/ki.2015.28. Epub 2015 Mar 4. Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management--A KDIGO consensus report. Eckardt KU1, Alper SL2, Antignac C3,4, Bleyer AJ5, Chauveau D6, Dahan K7, Deltas C8, Hosking A9, Kmoch S10, Rampoldi L11, Wiesener M1, Wolf MT12, Devuyst O13; Kidney Disease: Improving Global Outcomes." 3:alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 1 trials.the lan lancet et oncology. 4:Topical treatment of glaucoma: established and emerging pharmacology 5:Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.   [更多]
懸賞
¥50.00
已托管
載入中...
發(fā)布需求,坐等藥智客上門
  • 安全可靠,先驗(yàn)收再正式付款
  • 性價(jià)比超高,節(jié)省一半費(fèi)用
  • 80%的需求得到了圓滿解決
立即發(fā)布需求

推薦任務(wù)